NasdaqCM - Delayed Quote • USD
Brainstorm Cell Therapeutics Inc. (BCLI)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:53 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | -0.7 | -0.28 |
| Low Estimate | 0 | 0 | -0.7 | -0.28 |
| High Estimate | 0 | 0 | -0.7 | -0.28 |
| Year Ago EPS | -0.19 | -0.13 | -0.66 | -0.7 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2022 | 12/31/2022 | 3/31/2023 | 6/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.18 | -0.14 | -0.16 | -0.15 |
| EPS Actual | -0.19 | -0.13 | -0.14 | -0.27 |
| Difference | -0.01 | 0.01 | 0.02 | -0.12 |
| Surprise % | -5.60% | 7.10% | 12.50% | -80.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -0.7 | -0.28 |
| 7 Days Ago | -0.14 | -0.15 | -0.7 | -0.28 |
| 30 Days Ago | -0.14 | -0.15 | -0.7 | -0.47 |
| 60 Days Ago | -0.14 | -0.15 | -0.7 | -0.47 |
| 90 Days Ago | -0.14 | -0.15 | -0.7 | -0.47 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2023) | Next Qtr. (Dec 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BCLI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 2.60% |
| Next Qtr. | -- | -- | -- | 13.40% |
| Current Year | -6.10% | -- | -- | 5.20% |
| Next Year | 60.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Maxim Group: Buy to Hold | 9/28/2023 |
| Maintains | Maxim Group: Buy | 3/31/2023 |
| Upgrade | Maxim Group: Hold to Buy | 2/5/2021 |
| Initiated | HC Wainwright & Co.: Buy | 5/15/2018 |
| Maintains | Maxim Group: Buy | 8/17/2017 |
Related Tickers
KTRA Kintara Therapeutics, Inc.
0.1580
+15.08%
BLRX BioLineRx Ltd.
0.5753
-6.15%
AMLX Amylyx Pharmaceuticals, Inc.
1.7800
-5.32%
CLNN Clene Inc.
0.3465
+2.82%
KZIA Kazia Therapeutics Limited
0.3699
-4.91%
RNAZ TransCode Therapeutics, Inc.
0.5250
+19.35%
PBLA Panbela Therapeutics, Inc.
0.4400
+7.29%
PXMD PaxMedica, Inc.
0.7042
+1.76%
MAIA MAIA Biotechnology, Inc.
2.6800
-0.37%
CGTX Cognition Therapeutics, Inc.
1.9300
-3.02%